Asset Details
Do you wish to reserve the book?
The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients
Do you wish to request the book?
The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients
2025
Overview
Objectives
This study investigated the impact and related mechanisms of single-nucleotide variants (SNVs) in the HBV pre-S/S region on tumor development, and evaluated the role of antiviral therapy.
Methods
A retrospective analysis was conducted in 104 patients of the gray zone. HCC-associated SNVs were analyzed in baseline samples.
Results
HCC occurred in 15 patients (14.4%) during the median follow-up period of 10.4 years. Genotype B HBV-infected HCC patients had more T53C, A273G, and A529G SNVs and genotype C HBV-infected HCC patients had more T53C, G633A, and A3120G SNVs than HCC-free groups. Antiviral therapy reduced the risk of HCC in patients with HCC-associated SNVs in the gray zone both genotype B or C. Ectopic expression of replication-competent HBV plasmids in Huh7 cells expressing HCC-associated SNVs resulted in greater impairment of mitochondrial dynamics, increased production of reactive oxygen species (ROS), decreased mitochondrial membrane potential, lower ATP production, higher basal calcium levels, and reduced calcium buffering capacity compared to controls or wild-type HBV-expressing cells.
Conclusions
CHB patients in the gray zone remain at risk for HCC owing to both wild-type and HCC-associated HBV SNVs, especially the latter, inducing mitochondrial and metabolic dysfunctions. Antiviral therapy reduces the risk of HCC development in these patients.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Antiviral Agents - therapeutic use
/ Biomedical and Life Sciences
/ Carcinoma, Hepatocellular - genetics
/ Carcinoma, Hepatocellular - virology
/ Female
/ Hepatitis B virus - genetics
/ Hepatitis B, Chronic - complications
/ Hepatitis B, Chronic - drug therapy
/ Hepatitis B, Chronic - virology
/ Humans
/ Liver Neoplasms - epidemiology
/ Male
